Australian Clinical Labs Limited (ASX:ACL)
Australia · Delayed Price · Currency is AUD | Market Cap | 525.53M +6.0% |
| Revenue (ttm) | 736.15M -0.7% |
| Net Income | 23.71M -26.9% |
| EPS | 0.12 -23.9% |
| Shares Out | 185.05M |
| PE Ratio | 23.03 |
| Forward PE | 15.14 |
| Dividend | 0.13 (4.80%) |
| Ex-Dividend Date | Sep 2, 2026 |
| Volume | 477,960 |
| Open | 2.840 |
| Previous Close | 2.840 |
| Day's Range | 2.820 - 2.885 |
| 52-Week Range | 1.832 - 3.030 |
| Beta | 0.83 |
| Analysts | Hold |
| Price Target | 2.88 (0.0%) |
| Earnings Date | Aug 17, 2026 |
About Australian Clinical Labs
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers cardiac testing, gastroenterology, haematology, chemical pathology, antenatal testing, serology and microbiology, cervical screening, commercial drug and alcohol testing, STI Testing, veterinary pathology, molecular cancer services, clinical trials pathology, advanced genetic testing, functional pathology, histopathology and cytopathology, CPD education programs for clinicians, and allergy and immunology services. It also provides workplace ... [Read more]
Financial Performance
In fiscal year 2026, Australian Clinical Labs's revenue was 736.15 million, a decrease of -0.69% compared to the previous year's 741.27 million. Earnings were 23.71 million, a decrease of -26.89%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ACL stock is "Hold." The 12-month stock price target is $2.88, which is no change of 0.00% from the latest price.
News
Australian Clinical Labs Earnings Call Transcript: H2 2026
Underlying margins and EBIT improved above guidance despite revenue decline from fee cuts and low market volumes. Strategic exits, digital billing, and operational efficiencies drove margin gains, with strong cash conversion and capital returns. FY 2027 guidance targets stable margins and continued disciplined growth.
Australian Clinical Labs Slides: H2 2026
Australian Clinical Labs has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 16, 2026.
Australian Clinical Labs Annual report: H2 2026
Australian Clinical Labs has published its H2 2026 annual report on August 16, 2026.
Australian Clinical Labs Earnings Call Transcript: H1 2026
Underlying profitability and margins improved despite a 1% revenue decline, driven by operational discipline, digitalization, and portfolio optimization. Guidance anticipates H2 market recovery, with ongoing share buybacks and cost mitigation plans for wage increases.
Australian Clinical Labs Quarterly report: H1 2026
Australian Clinical Labs has published its H1 2026 quarterly earnings report on February 15, 2026.
Australian Clinical Labs Slides: H1 2026
Australian Clinical Labs has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 15, 2026.
Australian Clinical Labs Earnings release: H1 2026
Australian Clinical Labs released its H1 2026 earnings on February 15, 2026, summarizing the period's financial results.
Australian Clinical Labs Transcript: AGM 2025
The AGM highlighted strong financial growth, strategic expansion, and operational improvements, with $44 million returned to shareholders. Despite a second strike on the Remuneration Report, all director re-elections were supported, and a new share buyback was announced.
Australian Clinical Labs Slides: FY 2025
Australian Clinical Labs has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 22, 2025.